Literature DB >> 24606123

Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells.

Gwen E Dressing1, Todd P Knutson, Matthew J Schiewer, Andrea R Daniel, Christy R Hagan, Caroline H Diep, Karen E Knudsen, Carol A Lange.   

Abstract

The progesterone receptor (PR) and its coactivators are direct targets of activated cyclin-dependent kinases (CDKs) in response to peptide growth factors, progesterone, and deregulation of cell cycle inhibitors. Herein, using the T47D breast cancer model, we probed mechanisms of cell cycle-dependent PR action. In the absence of exogenous progestin, the PR is specifically phosphorylated during the G2/M phase. Accordingly, numerous PR target genes are cell cycle regulated, including HSPB8, a heat-shock protein whose high expression is associated with tamoxifen resistance. Progestin-induced HSPB8 expression required cyclin D1 and was insensitive to antiestrogens but blocked by antiprogestins or inhibition of specificity factor 1 (SP1). HSPB8 expression increased with or without ligand when cells were G2/M synchronized or contained high levels of cyclin D1. Knockdown of PRs abrogated ligand-independent HSPB8 expression in synchronized cells. Notably, PRs and cyclin D1 copurified in whole-cell lysates of transiently transfected COS-1 cells and in PR-positive T47D breast cancer cells expressing endogenous cyclin D1. PRs, cyclin D1, and SP1 were recruited to the HSPB8 promoter in progestin-treated T47D breast cancer cells. Mutation of PR Ser345 to Ala (S345A) or inhibition of CDK2 activity using roscovitine disrupted PR/cyclin D1 interactions with DNA and blocked HSPB8 mRNA expression. Interaction of phosphorylated PRs with SP1 and cyclin D1 provides a mechanism for targeting transcriptionally active PRs to selected gene promoters relevant to breast cancer progression. Understanding the functional linkage between PRs and cell cycle regulatory proteins will provide keys to targeting novel PR/cyclin D1 cross talk in both hormone-responsive disease and HSPB8-high refractory disease with high HSPB8 expression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24606123      PMCID: PMC3968407          DOI: 10.1210/me.2013-1196

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  81 in total

1.  Regulation of progesterone receptor activity by cyclin dependent kinases 1 and 2 occurs in part by phosphorylation of the SRC-1 carboxyl-terminus.

Authors:  Nicole L Moore; Nancy L Weigel
Journal:  Int J Biochem Cell Biol       Date:  2011-04-21       Impact factor: 5.085

2.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

3.  Progestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor beta induces proliferation of endometrial stromal cells.

Authors:  Griselda Vallejo; Cecilia Ballaré; José Lino Barañao; Miguel Beato; Patricia Saragüeta
Journal:  Mol Endocrinol       Date:  2005-07-14

Review 4.  Minireview: Cyclin D1: normal and abnormal functions.

Authors:  Maofu Fu; Chenguang Wang; Zhiping Li; Toshiyuki Sakamaki; Richard G Pestell
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

5.  Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes.

Authors:  Anna Chytil; Mary Waltner-Law; Robert West; David Friedman; Mary Aakre; Dana Barker; Brian Law
Journal:  J Biol Chem       Date:  2004-09-07       Impact factor: 5.157

6.  Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells.

Authors:  Andrea R Daniel; Carol A Lange
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

7.  Persistent nuclear accumulation of protein kinase CK2 during the G1-phase of the cell cycle does not depend on the ERK1/2 pathway but requires active protein synthesis.

Authors:  Francesc A Miro; Franc Llorens; Nerea Roher; Maria Plana; Néstor Gómez; Emilio Itarte
Journal:  Arch Biochem Biophys       Date:  2002-10-15       Impact factor: 4.013

8.  Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors.

Authors:  Ming Qiu; Abby Olsen; Emily Faivre; Kathryn B Horwitz; Carol A Lange
Journal:  Mol Endocrinol       Date:  2003-01-09

9.  LMTK3 is implicated in endocrine resistance via multiple signaling pathways.

Authors:  J Stebbing; A Filipovic; L C Lit; K Blighe; A Grothey; Y Xu; Y Miki; L W Chow; R C Coombes; H Sasano; J A Shaw; G Giamas
Journal:  Oncogene       Date:  2012-08-06       Impact factor: 9.867

10.  Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.

Authors:  Todd P Knutson; Andrea R Daniel; Danhua Fan; Kevin At Silverstein; Kyle R Covington; Suzanne Aw Fuqua; Carol A Lange
Journal:  Breast Cancer Res       Date:  2012-06-14       Impact factor: 6.466

View more
  23 in total

1.  Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.

Authors:  Yang Nan; Liyun Guo; Yunpeng Song; Le Wang; Kai Yu; Qiang Huang; Yue Zhong
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-11       Impact factor: 4.553

2.  Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer.

Authors:  Merit L Goodman; Gloria M Trinca; Katherine R Walter; Evangelia K Papachristou; Clive S D'Santos; Tianbao Li; Qi Liu; Zhao Lai; Prabhakar Chalise; Rashna Madan; Fang Fan; Mary A Markiewicz; Victor X Jin; Jason S Carroll; Christy R Hagan
Journal:  J Immunol       Date:  2019-04-01       Impact factor: 5.422

Review 3.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

Review 4.  Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance.

Authors:  Alex J Gooding; William P Schiemann
Journal:  Mol Cancer Res       Date:  2020-06-05       Impact factor: 5.852

Review 5.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

6.  O-GlcNAc-Dependent Regulation of Progesterone Receptor Function in Breast Cancer.

Authors:  Gloria M Trinca; Merit L Goodman; Evangelia K Papachristou; Clive S D'Santos; Prabhakar Chalise; Rashna Madan; Chad Slawson; Christy R Hagan
Journal:  Horm Cancer       Date:  2017-09-19       Impact factor: 3.869

7.  Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer.

Authors:  Katherine R Walter; Merit L Goodman; Hari Singhal; Jade A Hall; Tianbao Li; Sean M Holloran; Gloria M Trinca; Katelin A Gibson; Victor X Jin; Geoffrey L Greene; Christy R Hagan
Journal:  Mol Cancer Res       Date:  2017-07-06       Impact factor: 5.852

8.  Raman and coherent anti-Stokes Raman scattering microscopy studies of changes in lipid content and composition in hormone-treated breast and prostate cancer cells.

Authors:  Mariana C Potcoava; Gregory L Futia; Jessica Aughenbaugh; Isabel R Schlaepfer; Emily A Gibson
Journal:  J Biomed Opt       Date:  2014       Impact factor: 3.170

9.  Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming.

Authors:  Caroline H Diep; Todd P Knutson; Carol A Lange
Journal:  Mol Cancer Res       Date:  2015-11-17       Impact factor: 5.852

Review 10.  Tracking progesterone receptor-mediated actions in breast cancer.

Authors:  Todd P Knutson; Carol A Lange
Journal:  Pharmacol Ther       Date:  2013-11-26       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.